CASE REPORT

Effect of chemotherapy on autoimmune hepatitis in thymoma: a case report and literature review

Nesrine Mejri1, Imen Chabchoub1, Ines Gargouri1, Imtinen Belaid1, Faten Ezairi1, Sihem Hmissa2, Slim Ben Ahmed1

1Medical Oncology Department, Farhat Hached Hospital, Sousse 4011, Tunisia; 2Pathology Department, Farhat Hached Hospital, Sousse 4011, Tunisia

ABSTRACT

Autoimmune hepatitis (AIH) has rarely been described as an autoimmune paraneoplastic syndrome of thymoma. This case is the seventh case of AIH revealed by cholestasis few years after the diagnosis of thymoma and the first case treated with chemotherapy alone. We report in this paper a new approach to this rare severe condition. A 29 year-old man presented with chest pain and dyspnea with a history of thymoma surgically removed 4 years ago. CT scan showed the recurrence of an anterior mediastinal mass. Biology showed elevated liver enzymes and profound cholestasis. No sign of viral or toxic hepatitis or bile duct abnormalities were observed. Autoimmune antibodies, except for the anti-nuclear antibody, were negative. Liver biopsy showed active chronic AIH. The patient was diagnosed with recurrent thymoma with AIH and underwent 6 cycles of chemotherapy. A complete response on thymoma and cholestasis was obtained after 10 months of follow-up. Steroids and immunosuppressors are the standard treatment for AIH. The effect of chemotherapy as a specific treatment of this paraneoplastic syndrome needs to be considered.

KEYWORDS

Hepatitis; autoimmune; thymoma; chemotherapy

Introduction

Thymoma is the most frequent tumor of the thymus. The 2004 WHO classification considers three morphological types of thymoma according to genetic alterations (microsatellite instability, 6q25, 5q21-22 mutations): A, B (B1, B2, and B3), and AB. The B3 subtype is the most aggressive one with 50% overall survival within 5 years1. Median age at diagnosis is 50 years. Thymoma is a slow-growing tumor that can relapse after 10 years, implying lifelong follow-up. The rate of associated malignancy (e.g., lymphoma and lung sarcoma) is higher than that in the general population2. Many autoimmune paraneoplastic syndromes are associated with thymoma. The most popular such syndrome is myasthenia gravis, which occurs in 35% to 45% of cases. Other autoimmune diseases have been reported, such as systemic lupus erythematosus, Hashimoto’s thyroiditis, erythroblastopenia, type I diabetes mellitus, and in some cases, 2 or even 3 autoimmune diseases at the same time. Autoimmune hepatitis (AIH) associated with thymoma has rarely been reported, with fewer than 10 cases published in literature. AIH is a severe disease because it inhibits certain specific treatments of the primary tumor and destroys hepatic tissue and causes hepatocellular failure.

We report a new case of AIH associated with thymoma. The new finding about this case is that chemotherapy reduces biological signs of hepatitis without need for steroids or immunosuppressors. Through this case report and a review of literature, we highlight the clinical and therapeutic aspects of this rare entity.

Case report

A 29 year-old male with dyspnea and chest pain was referred to our center. Medical history showed diabetes mellitus and B1 subtype thymoma (stage II) surgically removed 4 years ago (Figure 1). The patient did not receive adjuvant therapy at that time and was not followed up since.
Physical examination showed no signs of heart failure or myasthenia gravis. ECG was normal. Chest X-ray revealed an enlargement of the upper mediastinum with small pleural effusion. CT scan showed a tissular mass of the anterior mediastinum with dimensions of 3 cm × 5 cm × 6 cm. This mass reached the mediastinum medium and came into contact with the pericardium. Small pleural and pericardial effusion was observed. Cytology examination of pleural liquid was negative. Core biopsy was technically difficult and life-threatening. The patient exhibited local recurrence of a thymic tumor. Chemotherapy was decided, and the patient was admitted to our center in March 2012.

Blood cell count, renal function, and calcemia were normal. We observed a biological inflammatory syndrome with accelerated sedimentation speed (90 in the first hour) and polyclonal hyper gamma-globulinemia (46 g/L), predominantly of type IgG. Profound cholestasis without pruritis or jaundice was observed: total bilirubin at 72 mg/dL (5× normal), gamma glutamyl transferase at 1,680 UI/L (30× normal), and alkaline phosphatase at 780 UI/L (6× normal). The level of aspartate aminotransferase (ASAT) was 56 UI/L (1.5× normal), and that of alanine aminotransferase (ALAT) was 63 UI/L (1.5× normal). Blood sugar levels were disturbed. No history of drug abuse, including herb consumption, was reported. Abdominal ultrasonography showed no liver or bile duct abnormalities. Viral markers of hepatitis B and C were negative. Anti-nuclear antibody content was high (1/800, type ant-DNA), and anti-mitochondrial antibodies, anti-liver/kidney microsomes (LKM1), and anti-smooth muscles were negative. A liver biopsy showed signs of active periportal necrosis and fibrosis with an infiltration of inflammatory cells, mainly lymphocytes and plasmocytes (Figure 2). According to the scoring system of the International AIH Group, the pre-treatment score was 13, which corresponds to the probable diagnosis of AIH.

The patient was subjected to 3 cycles of chemotherapy based on cyclophosphamide, cisplatine, doxorubicine, and vincristine (CACV, every three weeks), with 50% reduction of vincristine doses because of hepatic cholestasis. Steroids were not indicated because the diabetes of the patient was difficult to stabilize and cytolysis was low and thus could not indicate immediate treatment. No grade III/IV toxicity was observed. Evaluation after 3 cycles showed clinical relief, radiological complete response on the thymic tumor, partial regression of pleural effusion, and 50% reduction of biological cholestasis (Table 1). The post-treatment score was 17, which corresponds to a definitive diagnosis of AIH. Diabetes was stabilized with insulin doses. The patient received 3 more cycles of the same chemotherapy. CT scan evaluation showed partial regression of the pleural effusion and normal liver lab values. The patient was considered to be in complete remission. He was recommended for mediastinal radiotherapy. At the time of this writing, the patient is asymptomatic with normal cholestasis markers and CT scan after 14 months of follow-up.

**Figure 1** Type B thymoma, cytokeratine positive staining (IHC×40).

**Figure 2** Lymphocyte infiltration and paracellular necrosis (H&E×40).

**Table 1** Evolution of liver enzymes

| Liver enzymes              | Before chemotherapy | After 3 cycles of chemotherapy | After 6 cycles of chemotherapy |
|----------------------------|---------------------|--------------------------------|--------------------------------|
| Gamma globulin (g/L)       | 46                  | 35                             | 24                             |
| Total bilirubin (mg/dL)    | 72                  | 40                             | 11                             |
| Gamma glutamyl transferase (UI/L) | 1,680              | 1,050                          | 230                           |
| Alkaline phosphatase (UI/L) | 780                 | 580                            | 210                            |
| Aspartate aminotransferase (UI/L) | 56                  | 20                             | 18                             |
| Alanine aminotransferase (UI/L) | 63                  | 22                             | 20                             |
| Reference | Age, yrs | Gender | Clinical presentation | Biology (UI/L) | Radiology | Pathology | Other paraneoplastic symptoms | Treatment | Evolution and follow up |
|-----------|---------|--------|-----------------------|----------------|-----------|-----------|-----------------------------|-----------|------------------------|
| Ko et al.1 | 25 F    | F      | Incidental            | Not mentioned  | ASAT: 1158| PAL: 106  | Sm--/LKM1--               | Prednisolone | ASAT/ALAT normal after 2 months |
| Han et al.2 | 30 M    | M      | Weakness              | ASAT: 400      | ALAT: 777 | ANA+      | ASM--/AM--               | Prednisolone | ASAT/ALAT normal after 1 month |
| Askawa et al.3 | 77 F    | F      | Fatigue               | ANA+           | ASAT: 381 | ALAT: 22  | LKM1--/AM--              | Vitamin K    | Plasmapheresis          |
| Kim et al.4  | 35 No   | No     | Jaundice, Ascitis     | ANA+           | ASAT: 25  | ALAT: 122 | LKM1--                   | Prednisolone | Normal biology for 36 months |
| Aigner et al.5 | 56 M    | M      | Loss of appetite      | ANA/ASM+       | ASAT: 1912 | ALAT: 1332| AIH revealing thymoma     | Prednisolone | Normal biology for 48 months |
| Yapali et al.6 | 31 F    | F      | Jaundice, Nausea      | ANA/ASM--      | ASAT: 269 | ALAT: 249 | LKM1--                   | Prednisolone | Normal biology for 6 months  |

M, male; F, female; ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase; PAL, alkaline phosphatase; GT, gamma glutamyl transferase; AAN, anti-nuclear antibody; ASM, anti smooth muscle antibody; AM, anti mitochondrial antibody; LKM1, anti liver/kidney microsome antibody.
**Discussion**

Chemotherapy can be an efficient treatment of paraneoplastic disorders. This case is a combination of two autoimmune diseases associated with thymoma: type 1 diabetes mellitus, which occurred when thymoma was first diagnosed, and AIH. We cannot ensure that the diabetes was totally related to the thymoma, but based on chronological events and the absence of familial history, we considered it as a paraneoplastic syndrome. AIH was diagnosed with disease recurrence, but its onset was difficult to define. Signs of fibrosis suggest chronic evolution. All cases published in literature are summarized in Table 2. In these cases, AIH appeared a few months after the diagnosis of thymoma in 1 case but was synchronous to diagnosis in the other cases. Most patients were from Asia, leading us to ask about genetic factors associated with high risk of AIH. Most patients were young, with a median age of 39 years. All 4 females and 2 males had no specific clinical presentation. AIH is generally revealed by biological liver dysfunction, with elevated liver enzymes (ASAT/ALAT). In our case, liver enzymes were slightly abundant, but major biological cholestasis was observed. The only case in literature on cholestasis associated with thymoma is related to autoimmune cholangitis.

Liver biopsy is always necessary to confirm diagnosis, which relies on the criteria of the International AIH Group. The International AIH Scoring System considers several parameters, such as gender, liver enzymes, antibodies, and concurrent autoimmune disease. Once the patient obtains a score of 15 before treatment or of 17 after treatment, the diagnosis of AIH is definite. Thymoma is a slow-growing disease that generally leads to liver failure, if not treated, in 50% of cases. The main treatment based on steroids and azathioprine can prevent evolution to cirrhosis. Asakawa et al. reported a case of AIH with rapid liver failure and death in the absence of a specific treatment of thymoma. In this case, the patient did not receive azathioprine because of the high risk of immune deficiency associated with chemotherapy and did not receive steroids because cytolysis was not profound. Cholestasis decreased markedly after chemotherapy alone. In a case reported by Asakawa, the fact that the patient could not be operated on her thymoma may explain the fatal evolution. In this case, chemotherapy allowed complete response on the primary tumor and corrected hepatic disorder.

Our hypothesis is also highlighted by the clinical and molecular data reported by Aigner, who showed the presence of LKM-3 and UGT 1 antibody (UDP glutamyl-transferase involved in AIH) in the patient’s serum, liver, and thymoma tissue. After thymectomy, these antibodies were not found in the serum of the patient. This paper showed the paraneoplastic origin of AIH (which occurred before the diagnosis of thymoma) and the effect of the surgical removal of the primary tumor on correcting this disorder. The active chemotherapy drugs are anthracyclines, cisplatine, and cyclophosphamide. New-generation chemotherapy drugs (pemetrexed, docetaxel, and irinotecan) produced controversial results. If the tumor seems responsive after 3 cycles, it is recommended to consolidate with 3 more cycles. Thymoma is a radiosensitive tumor and residual disease can be monitored with complementary mediastinal radiotherapy. Unlike already published cases, multimodality treatment using chemotherapy and radiotherapy was sufficient to control both the primary tumor and the paraneoplastic hepatic disorder of our patient.

**Conclusion**

Thymoma is associated with the high rate of paraneoplastic autoimmune diseases among AIH that should be considered in the etiological diagnosis of hepatic disorders in thymoma. In this case, based on chronological arguments, we speculated that AIH and diabetes mellitus are induced by thymoma. Specific treatments of the primary tumor may treat AIH. Immunosuppressors and steroids should be used only in case of severe evolution or a persistent paraneoplastic disorder.

**Conflict of interest statement**

No potential conflicts of interest are disclosed.

**References**

1. Ströbel P, Marx A, Zettl A, Müller-Hermelink HK. Thymoma and thymic carcinoma: an update of the WHO Classification 2004. Surg Today 2005;35:805-811.
2. Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010;5:S260-265.
3. Ko KF, Ho T, Chan KW. Autoimmune chronic active hepatitis and polymyositis in a patient with myasthenia gravis and thymoma. J Neurol Neurosurg Psychiatry 1995;59:558-559.
4. Han YS, Kim BH, Kim TH, Dong SH, Kim HJ, Chang YW, et al. Autoimmune hepatitis in a patient with myasthenia gravis and thymoma-a report on the first case in Korea. Korean J Intern Med 2000;15:151-155.
5. Asakawa H, Kashiwara T, Fukuda H, Yamamoto M. A patient with thymoma and four different organ-specific autoimmune disease. Neth J Med 2002;60:292-295.
6. Kim JH, Kim BH, Kim YW, Park JC, Jung YH, Lee BO, et al. Autoimmune cholangitis in a patient with thymoma. Journal of gastroenterology and hepatology 2004;19:1324-1327.
7. Aigner E, Strassburg CP, Strasser M, Pohla-Gubo G, Dietze O,
Hutter J, et al. Transient autoimmune hepatitis induced by a thymoma. Am J Gastroenterol 2009;104:1332-1334.

8. Yapali S, Oruc N, LLgum S, Yilmaz F, Aksu K, Yimlaz M, et al. Acute presentation of autoimmune hepatitis in a patient with myasthenia gravis, thymoma, Hashimoto thyroiditis and connective tissue disorder. Hepatol Res 2012;42:835-839.

9. Johnson PJ, McFarlane IG. Meeting report: international autoimmune hepatitis group. Hepatology 1993;18:998-1005.

10. Czaja A, Carpenter HA. Validation of scoring system for diagnosis of autoimmune hepatitis. Dig Dis Sci 1996;41:305-314.

11. Pescarmona E, Rendina EA, Venuta F, D’Arcangelo E, Pagani M, Ricci C, et al. Analysis of prognostic factors and clinicopathological staging of thymoma. Ann Thorac Surg 1990;50:534-538.

Cite this article as: Mejri N, Chabchoub I, Gargouri I, Belaid I, Ezairi F, Hmissa S, Ben Ahmed S. Effect of chemotherapy on autoimmune hepatitis in thymoma: a case report and literature review. Cancer Biol Med 2013;10:169-173. doi: 10.7497/j.issn.2095-3941.2013.03.008